Credit: Shutterstock photoIgnyta, a clinical-stage biotech developing targeted cancer therapeutics, raised $48 million by offering 5.2 million shares at $9.15. The deal size was 20% greater than expected. Ignyta, which has traded with very low volume on the OTCQB and OTCBB since December 2013, will list on the NASDAQ under the symbol RXDX. Leerink Partners was the sole bookrunner on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
